SOX2 Regulates Growth, Expression of Basal/Luminal Markers, and Chemotherapy Response in Urothelial Carcinoma
Cells · 2025
DOI: 10.3390/cells14130949 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Nelofar Nargis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND 58202, USA. Hauptthemen laut MEDLINE: SOXB1 Transcription Factors, Biomarkers, Tumor, Urinary Bladder Neoplasms, Urothelium. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, National Institute of General Medical Sciences, NIH.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Urothelial carcinoma (UC) is a common genitourinary malignancy. Smoking, exposure to arsenic in drinking water, and age can increase the risk of developing UC. Neoadjuvant cisplatin-based chemotherapy prior to radical cystectomy is the standard treatment for the muscle invasive form of UC (MIUC). Tumors of the basal/squamous (Ba/Sq) subtype of MIUC are aggressive, express basal keratins (KRT5, 6, and 14), are associated with squamous differentiation (SD), and frequently develop chemotherapy resistance. The SOX2 transcription factor is a marker of UC stem cells, and its expression is associated with poor overall and disease-free survival. We hypothesized that the attenuation of SOX2 would reduce the expression of basal keratins and increase the chemotherapy response in human UC cells. For this study, we performed lentiviral knockdown (KD) of SOX2 expression in two separate arsenite (As3+)-transformed UROtsa (As_I, As_II), 5637, and RT4 cells. Cellular growth and colony-forming ability was inhibited in all UC cell lines after SOX2 KD. We demonstrate that SOX2 KD in the UC cells of the Ba/Sq subtype (As_I, As_II, 5637) decreased the expression of stem-associated proteins, oncoproteins, and basal keratins. Additionally, there was an induction of several luminal markers and enhanced cisplatin sensitivity following the repression of SOX2. Lastly, proteomics revealed reductions in lipid-, cholesterol-, and interferon-signaling pathways after SOX2 KD. This study provides a better understanding of the regulation of key genes responsible for defining the Ba/Sq subtype of UC and demonstrates that the inhibition of SOX2 improves chemotherapy response in UC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND 58202, USA.
ORCID-Profile: Nelofar Nargis, Adam Sczepanski
Förderung
- NIGMS NIH HHS
- NIH HHS
- National Institute of General Medical Sciences, NIH
Zitieren
APA
Nargis, N., Lind, A., Sczepanski, A., Herndon, R., Smiley, O., Somji, S., Sens, D. A., & Mehus, A. A. (2025). SOX2 Regulates Growth, Expression of Basal/Luminal Markers, and Chemotherapy Response in Urothelial Carcinoma. Cells. https://doi.org/10.3390/cells14130949
Vancouver
Nargis N, Lind A, Sczepanski A, Herndon R, Smiley O, Somji S, et al. SOX2 Regulates Growth, Expression of Basal/Luminal Markers, and Chemotherapy Response in Urothelial Carcinoma. Cells. 2025. doi:10.3390/cells14130949
BibTeX
@article{Nargis2025,
author = {Nargis, Nelofar and Lind, Abigail and Sczepanski, Adam and Herndon, Randi and Smiley, Olivia and Somji, Seema and Sens, Donald A and Mehus, Aaron A},
title = {SOX2 Regulates Growth, Expression of Basal/Luminal Markers, and Chemotherapy Response in Urothelial Carcinoma},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14130949}
}
EUVIMED